Related Experiment Video
Updated: Jun 3, 2025
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Yuzhu Chen1,2, Fei Qi1,2, Chenhao Sun3
1Department of Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Abstract:
Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, despite these promising results, there is ongoing debate regarding the efficacy of immunological combination therapy strategies, the prevalence of treatment-related side effects, the identification of predictive biomarkers, and various other challenges within the neoadjuvant context. Careful consideration is essential to maximize the benefits of immunotherapy for patients with resectable NSCLC. This article offers a detailed overview of recent advancements in neoadjuvant immunotherapy for resectable NSCLC. By examining these developments, we aim to provide new perspectives and valuable insights into the benefits and challenges of applying neoadjuvant immunotherapy in clinical settings.
Insights
Neoadjuvant immunotherapy shows promise for resectable non-small-cell lung cancer (NSCLC). This review explores recent advancements, benefits, and challenges of using immunotherapy before surgery for NSCLC patients.
Area of Science:
- Oncology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are increasingly studied for non-small-cell lung cancer (NSCLC).
- Immunotherapy demonstrates potential in improving outcomes for resectable NSCLC.
- Neoadjuvant immunotherapy for NSCLC faces challenges including efficacy, side effects, and biomarkers.
Purpose of the Study:
- To provide a comprehensive overview of recent advancements in neoadjuvant immunotherapy for resectable NSCLC.
- To examine the benefits and challenges associated with neoadjuvant immunotherapy in clinical settings.
- To offer new perspectives on optimizing immunotherapy strategies for NSCLC.
Main Methods:
- Review of recent clinical studies and advancements in neoadjuvant immunotherapy for NSCLC.
- Analysis of efficacy, safety, and biomarker research in the neoadjuvant setting.
- Examination of challenges and future directions in NSCLC immunotherapy.
Main Results:
- Neoadjuvant immunotherapy is a developing strategy for resectable NSCLC.
- Ongoing research focuses on combination therapies and predictive biomarkers.
- Understanding treatment-related side effects is crucial for patient management.
Conclusions:
- Neoadjuvant immunotherapy offers significant potential for patients with resectable NSCLC.
- Further research is needed to address current challenges and maximize therapeutic benefits.
- Personalized approaches are essential for successful neoadjuvant immunotherapy application in NSCLC.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...